J Clin Oncol:选择性雌激素受体降解剂(Elacestrant)对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效:III期临床研究EMERALD

2022-05-25 yd2015 网络

研究表明,Elacestrant是首个口服选择性ER降解剂,在总体人群和ESR1突变患者中,与SOC相比,显示了显著的PFS改善,且安全性可控。

近期,Journal of Clinical Oncology杂志上发表了一项III期临床研究EMERALD结果,评估选择性雌激素受体降解剂(Elacestrant)对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效。

EMERALD是一项随机、开放标签的III期临床试验,评估选择性雌激素受体降解剂(Elacestrant)对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效。主要终点是所有患者和ESR1突变患者的无进展生存期(PFS)。

2019年2月至2020年10月期间筛查的694名患者中,477名患者被随机分配,分别接受Elacestrant(239名患者)或SOC治疗(238名患者)。中位年龄63岁(范围24-89),228例(47.8%)患者检测到ESR1突变。大多数患者内脏转移(163例[68.2%],Elacestrant和169例[71%],SOC治疗)。

在所有患者中,BICR评估的PFS在Elacestrant组与SOC组相比有统计学意义的延长(HR= 0.70;95% CI, 0.55 ~ 0.88;P=0.002)和ESR1突变患者(HR 5 0.55;95% CI, 0.39 ~ 0.77 P=0.0005)。在所有患者中,Elacestrant组和SOC组6个月的PFS率分别为34.3% (95% CI, 27.2 - 41.5)和20.4% (95% CI, 14.1 - 26.7),在ESR1突变患者中分别为40.8% (95% CI, 30.1 - 51.4)和19.1% (95% CI, 10.5 - 27.8)。同样,所有患者12个月的PFS率分别为22.3% (95% CI, 15.2 - 29.4)和9.4% (95% CI, 4.0 - 14.8),而ESR1突变患者的PFS率分别为26.8% (95% CI, 16.2 - 37.4)和8.2% (95% CI, 1.3 - 15.1)。

在二次分析中,排除既往或治疗期间使用氟维司群的患者,无论是在总体人群还是ESR1突变队列中,在统计学意义上,Elacestrant较对照组改善中位PFS (2.8个月vs 1.9个月;3.8个月vs 1.9个月)(p=0.0019;p=0.0006),6个月PFS率(34.3% vs 20.6%; 40.8% v 19.3%), 12个月PFS率(22.3% v 9.5%;26.8% v 8.3%)。

在对OS的中期分析中,所有患者发生149次事件,HR为0.75 (95% CI, 0.54 - 1.04;P=0.08);在ESR1突变患者中,共发生68起事件,HR为0.59 (95% CI, 0.36 - 0.96;P=0.03)。在没有ESR1突变的患者中,发生81起事件,HR为0.92 (95% CI, 0.59 - 1.42;P=0.69)。

治疗相关的3/4级不良事件发生在接受Elacestran治疗的患者中占7.2%,接受SOC治疗的患者占3.1%。导致中断治疗的治疗相关不良事件在Elacestran中为3.4%,SOC为0.9%。服用Elacestran的患者中有35.0%发生任何级别的恶心,而服用SOC的患者中有18.8%发生任何级别的恶心(3/4级分别为2.5%和0.9%)。

综上,研究表明,Elacestrant是首个口服选择性ER降解剂,在总体人群和ESR1突变患者中,与SOC相比,显示了显著的PFS改善,且安全性可控。

 

原始出处:

Bidard FC, Kaklamani VG, Neven P,  et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338. Epub ahead of print. PMID: 35584336.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
    2023-04-22 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
    2023-02-18 juliusluan78
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
    2023-04-24 bsmagic9140
  5. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
    2023-03-10 shanyongle
  8. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
    2023-03-05 gwc392
  9. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1866614, encodeId=82781866614df, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Apr 22 13:17:00 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653246, encodeId=51151653246ed, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Apr 15 02:17:00 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916553, encodeId=e98e19165530a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 18 14:17:00 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657643, encodeId=6a53165e6432d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Apr 24 04:17:00 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650054, encodeId=43e01650054a8, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Fri Mar 17 23:17:00 CST 2023, time=2023-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739138, encodeId=07bc1e3913811, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Oct 25 18:17:00 CST 2022, time=2022-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656108, encodeId=24ca165610859, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Fri Mar 10 12:17:00 CST 2023, time=2023-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682734, encodeId=62fe1682e34fc, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun Mar 05 12:17:00 CST 2023, time=2023-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922999, encodeId=2ab61922999ef, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Sep 29 02:17:00 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051782, encodeId=b5eb2051e823d, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 04 03:17:00 CST 2022, time=2022-10-04, status=1, ipAttribution=)]